Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

13.08.13	ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1 (PR Newswire)
06.08.13	Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly (PR Newswire)
05.08.13	Short Interest Activity for Today's Leaders with Bullish Growth Trends - GRILLiT, Sirius, Pfizer, Nokia, Intel (PR Newswire)
31.07.13	Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint (PR Newswire)
30.07.13	Pfizer Profit Surges On Zoetis Spinoff, Patent Settlement Gains; Backs Forecast (RTTNews)
29.07.13	Pfizer To Internally Separate Its Branded, Generic Businesses - Update (RTTNews)
29.07.13	Pfizer Plans To Internally Separate Commercial Operations Into Three Segments (RTTNews)
25.07.13	CHMP Confirms Prior Opinion Regarding Marketing Authorization in Europe for Pfizer’s XELJANZ® (tofacitinib citrate) (Businesswire)
24.07.13	Technical Briefing: Pfizer, Merck & Co., AbbVie, and Zogenix (PR Newswire)
24.07.13	Mylan Reaches Tarceva Settlement Agreement With OSI, Pfizer And Genentech (RTTNews)
23.07.13	Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth - Research Report on Pfizer, Merck & Co., Cubist, AstraZeneca and Impax (PR Newswire)
17.07.13	Reports: Pfizer, Amgen Among Five Potential Suitors For Onyx (RTTNews)
15.07.13	Pfizer Provides Update On Global Regulatory Approvals For Tofacitinib (RTTNews)
11.07.13	RMTI Cruises Ahead, ALNY, CELG Touch New Highs, BIOD Progresses (RTTNews)
11.07.13	FDA Accepts Eliquis SNDA For Review - Quick Facts (RTTNews)
10.07.13	Nu Skin Glows, It's Smile Time For CRY, INO Making Big Moves, PCYC On Watch (RTTNews)
10.07.13	Pfizer's Pneumococcal Vaccine Prevenar 13 Gets EU Nod For Expanded Use (RTTNews)
10.07.13	EU OKs Pfizer To Expand Use Of Prevenar 13 To Adults Aged 18-49 Yrs (RTTNews)
11.10.12	Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02: (Businesswire)
10.10.12	New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1 (Businesswire)
21.09.12	ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation (Businesswire)
21.09.12	ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation (Businesswire)
04.09.12	Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib) (Businesswire)
15.08.12	Pfizer Commences Consent Solicitation for Amendments to Pharmacia Indentures (Businesswire)
10.08.12	Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC) (Businesswire)
06.08.12	Summertime Shines a Light on the Need for Vitamin D (Businesswire)
31.07.12	Pfizer Reports Second-Quarter 2012 Results (Businesswire)
19.07.12	Pfizer and Northwestern University Win LYRICA® Patent Case in Delaware District Court (Businesswire)
28.06.12	Pfizer Declares A 22-Cent Third-Quarter 2012 Dividend (Businesswire)
26.06.12	Pfizer Invites Public to View and Listen to Webcast of July 31 Conference Call with Analysts (Businesswire)
21.06.12	FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review (Businesswire)
20.06.12	Pfizer Statement Regarding Prevnar 13® Receiving ACIP Recommendation for Prevention of Pneumococcal Disease in Adults With Immunocompromising Conditions (Businesswire)
19.06.12	Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (Businesswire)
18.06.12	FDA Issues Complete Response Letter For Pfizer’s Tafamidis Meglumine New Drug Application (Businesswire)
18.06.12	Have Americans Reached a New Era of Optimism about Aging? (Businesswire)
07.06.12	Pfizer Provides Update On Animal Health Strategic Alternatives Review Process (Businesswire)
25.05.12	Pfizer’s Axitinib Receives Positive Opinion from the Committee for Human Medicinal Products for the Second-line Treatment of Advanced Kidney Cancer in the EU (Businesswire)
23.05.12	Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units (Businesswire)
22.05.12	Pfizer Invites Public to View and Listen to Webcast of June 3 Pfizer Analyst and Investor Meeting at ASCO (Businesswire)
18.05.12	Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients (Businesswire)
15.05.12	Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) (Businesswire)
14.05.12	Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting (Businesswire)
10.05.12	Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference (Businesswire)
09.05.12	FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (Businesswire)
07.05.12	Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ® (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults (Businesswire)
04.05.12	Pfizer Reports Top-Line Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy (Businesswire)
04.05.12	Pfizer Stops Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Neuropathic Pain Associated With HIV Neuropathy (Businesswire)
02.05.12	Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase alfa) For The Treatment Of Gaucher Disease (Businesswire)
01.05.12	Pfizer Reports First-Quarter 2012 Results (Businesswire)
01.05.12	Pfizer Inc. Issues Statement Regarding Pending Court Case (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

30.12.24		Montagshandel in New York: Dow Jones fällt schlussendlich zurück
30.12.24		Dow Jones aktuell: Dow Jones schwächelt am Montagnachmittag
30.12.24		XETRA-Handel TecDAX präsentiert sich zum Ende des Montagshandels schwächer
30.12.24		Börse Zürich in Grün: SMI steigt schlussendlich
30.12.24		STOXX-Handel Euro STOXX 50 gibt zum Ende des Montagshandels nach
30.12.24		FTSE 100-Handel aktuell: FTSE 100 fällt zum Handelsende
30.12.24		Aufschläge in Zürich: SPI beendet den Handel im Plus
30.12.24		MDAX aktuell: MDAX zum Handelsende im Minus

30.12.24

Montagshandel in New York: Dow Jones fällt schlussendlich zurück

30.12.24

Dow Jones aktuell: Dow Jones schwächelt am Montagnachmittag

30.12.24

XETRA-Handel TecDAX präsentiert sich zum Ende des Montagshandels schwächer

30.12.24

Börse Zürich in Grün: SMI steigt schlussendlich

30.12.24

STOXX-Handel Euro STOXX 50 gibt zum Ende des Montagshandels nach

30.12.24

FTSE 100-Handel aktuell: FTSE 100 fällt zum Handelsende